Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A

SSZSE:300255
17.39
CNY
-0.43
(-2.41%)
-0.39EPS
21.08BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.83
0.94
1.05
1.27
1.51
1.77
2.21
2.52
3.18
2.67
1.54
1.12
0.95
1.01
Basic EPS, GAAP
0.14
0.16
0.18
0.2
0.21
0.15
0.24
0.27
0.25
0.02
-1.35
-0.27
-0.39
-0.38
Free Cash Flow per Basic Share
-0.33
-0.27
-0.14
0.09
- -
0.06
-0.24
-0.41
-0.33
-0.49
-0.22
-0.2
-0.07
- -
Dividend per Share
0.04
0.03
0.06
0.06
0.05
0.07
0.08
0.07
0.07
0.14
0.12
0.13
0.13
0.13
Book Value per Share
1.45
1.62
1.79
2.38
2.53
2.69
2.9
3.05
3.28
3.27
1.97
1.7
1.31
1.27
Tangible Book Value per Share
1.29
1.46
1.63
2.17
2.26
2.4
2.6
2.61
2.75
2.68
1.23
0.9
0.44
0.36
Basic Weighted Avg Shares
850
860
868
877
938
933
939
936
934
876
919
924
918
919
Sales/Revenue/Turnover
705
811
916
1,118
1,420
1,653
2,071
2,364
2,968
2,336
1,410
1,031
875
930
Operating Margin (%)
20.71
21.17
22.27
20.22
18.63
17.42
15.29
16.14
11.37
5.81
-33.62
-9.37
-10.6
-4.34
Depreciation Expense
17
28
32
37
42
46
52
55
56
57
75
74
70
- -
Net Income, GAAP
115
134
156
175
197
140
225
253
234
18
-1,240
-249
-358
-351
Effective Tax Rate (%)
14.5
14.38
15.84
12.66
15.1
22.87
14.83
16.72
11.19
43.94
- -
- -
- -
- -
Profit Margin (%)
16.35
16.48
17.06
15.69
13.87
8.47
10.88
10.7
7.87
0.75
-87.93
-24.2
-40.9
-37.73
Working Capital
806
634
717
1,369
1,542
1,516
1,346
1,587
1,674
2,110
355
-200
-772
-794
LT Debt
- -
- -
- -
68
200
200
- -
281
332
1,129
813
663
585
683
Total Equity
1,286
1,427
1,571
2,289
2,435
2,523
2,722
2,853
3,072
3,054
1,800
1,536
1,168
1,122
Return on Invested Capital (%)
7.73
7.2
7.14
6.81
6.49
3.91
6.21
6.56
5.16
0.22
- -
- -
- -
- -
Return on Capital (%)
8.94
8.97
8.99
7.84
7.17
5.42
7.63
7.83
6.53
1.5
- -
- -
- -
- -
Return on Common Equity (%)
9.89
10.29
10.84
9.38
8.56
5.73
8.62
9.09
7.9
0.57
-50.94
-14.79
-25.87
-26

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,900
1,971
1,912
LT Borrowings
776
815
683
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
919
919
919
Market Capitalization
34,354
21,524
21,083

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,778
1,820
1,619
Cash, Cash Equivalents & STI
187
180
72
Accounts Receivable, Net
304
370
420
Inventories
1,181
1,144
1,055
Total Current Liabilities
2,396
2,442
2,413
Payables & Accruals
- -
- -
- -
ST Debt
1,900
1,971
1,912
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.42%
-14.52%
-23.94%
Free Cash Flow
58.67%
-21.2%
-63.09%
Net Income, GAAP
-724.93%
-1,463.6%
43.46%
Sales/Revenue/Turnover
2.75%
-15.48%
-15.1%
Total Cash Common Dividend
12.89%
17.58%
-1.03%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
294
273
216
247
1,031
2025
259
233
- -
194
875
2026
256
220
261
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
0.02
0.06
-0.28
-0.27
2025
- -
-0.04
- -
-0.34
-0.39
2026
0.01
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.04
0.13
2025
0.03
0.03
- -
0.03
0.13
2026
0.03
0.04
0.02
- -
- -

Company Description

CEO
Xiao Dong Gao
Full Time Employees
1,194
Sector
Health technology
Industry
Biotechnology
Address
No. 71 Menglong Street, South Zone Shijiazhuang HE China 050800
IPO Date
Aug 5, 2011
Business
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biochemical pharmaceutical products with a focus on heparin series products. The company’s core product portfolio includes heparin sodium active pharmaceutical ingredients (APIs); crude heparin; low molecular weight heparins (LMWH) such as enoxaparin sodium, nadroparin calcium, and dalteparin sodium; heparin calcium injections; heparin sodium injections; heparin lithium injectables; sodium hyaluronate in both cosmetic and food-grade forms; hard capsules; anti-aging dietary supplements branded as Yihaitang capsules; and additional finished dosage forms like small-volume injections. These products primarily target the prevention and treatment of cardiovascular and cerebrovascular diseases, including cerebral vascular conditions, arteriosclerosis, myocardial infarction, and phlebitis. The company also is involved in the expansion of its portfolio into multidisciplinary innovative drugs, including diabetes treatment and antineoplastic drugs. Hebei Changshan operates under GMP standards and distributes its products domestically in China and internationally across countries including the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, and the Philippines. Founded in 2000 and headquartered in Hebei, China, the company has established a strong technical team and a complete heparin industrial chain supporting its product lines. Recent significant developments include the clinical trial approval of Aibennatide, a GLP-1 receptor agonist injection for weight loss indications, complementing its prior approval application for type 2 diabetes treatment. The company’s controlling shareholder planned a strategic divestment by selling a 5% stake valued at approximately 2.1 billion yuan in 2025. Hebei Changshan has also been advancing its R&D focus on innovative therapies such as NTRK inhibitors and c-Met targeted antineoplastic agents, reflecting a shift toward pharmaceutical innovation and precision medicine. The company’s strategic expansions incorporate commercial insurance breakthroughs for innovative drugs and growth in overseas authorization trades, aligning with industry trends and regulatory changes in China’s pharmaceutical sector. These moves indicate Hebei Changshan's commitment to evolving beyond its established heparin products into broader biopharmaceutical research and international market penetration. Hebei Changshan Biochemical Pharmaceutical Co., Ltd. remains a key player in the biochemical pharmaceutical industry with strong positions in heparin APIs and preparations, operating globally with a strategic emphasis on cardiovascular, cerebrovascular, diabetes, and oncology therapeutic areas. Its comprehensive product range, robust technical capabilities, ongoing innovative drug development, and recent strategic investments underscore its growth trajectory within China and international markets.